The Clinical Trials Network for the Prevention and Early Treatment of Acute Lung Injury (PETAL Network) is a network of 12 Clinical Centers (CC) and 1 Clinical Coordinating Center (CCC) funded by the National Heart, Lung, and Blood Institute (NHLBI) to develop and conduct randomized controlled clinical trials to prevent Acute Respiratory Distress Syndrome (ARDS) or provide early treatment to improve the outcome of patients who have ARDS. The PETAL Network is seeking your input and feedback.
The PETAL Network welcomes future prevention and early treatment trial ideas from the US and international acute care and critical care community.
Please enter your comments and ideas here: http://petalnet.org/bb.
|Thompson, B. Taylor, MD (Chair)||Massachusetts General Hospital (CCC)|
|Angus, Derek C, MD||UPMC Presbyterian|
|Gong, Michelle Ng, MD||Montefiore Moses|
|Hou, Peter C, MD||Brigham and Women's Hospital|
|Park, Pauline K, MD||University of Michigan Medical Center|
|Shapiro, Nate, MD||Beth Israel Medical Center|
|Steingrub, Jay S, MD||Baystate Medical Center|
|Talmor, Daniel, MD||Beth Israel Medical Center|
|Thompson, B. Taylor, MD||Massachusetts General Hospital (CCC)|
|Yealy, Donald M, MD||UPMC Presbyterian|
An international advisory committee (IAC) has also been formed to facilitate dialog and coordination of research efforts with US and international experts and other clinical trials groups. Plans for their first meeting are in process. Please check back here for updates on their activities.
It is with the heaviest of hearts and deepest sorrow that the PETAL Network notes the passing of Arthur “Art” P. Wheeler on December 17th, 2015.
On May 20th, PETAL Network investigators presented an update on the Network's activities to attendees of the American Thoracic Society's 2015 International Meeting held in Denver Colorado.
Highlights from the presentation:
Statin therapy does not prevent exacerbations of chronic obstructive pulmonary disease (COPD) or lower mortality from acute respiratory distress syndrome (ARDS), report two studies that rigorously tested the benefit of the cholesterol-lowering drugs on outcomes in the lung diseases.